NanoViricides, Inc. (NYSE: NNVC) is a nano-biopharmaceutical company focused on discovering, developing, and marketing therapeutics for the treatment of viral infections. The company is developing anti-flu drug candidates at pre-clinical and advanced pre-clinical stage.  These candidates include two FluCide drugs made up of NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for novel strain of H7N9, Bird Flu H5N1, and other Pathogenic Influenzas. For more information, visit the company’s website at www.nanoviricides.com